[ad_1]
Zamboni, M. M., da Silva, C. T. Jr., Baretta, R., Cunha, E. T. & Cardoso, G. P. Essential prognostic elements for survival in sufferers with malignant pleural effusion. BMC Pulm. Med. 15, 29 (2015).
Murthy, P. et al. Making chilly malignant pleural effusions scorching: driving novel immunotherapies. Oncoimmunology 8, e1554969 (2019).
Morgensztern, D., Waqar, S., Subramanian, J., Trinkaus, Ok. & Govindan, R. Prognostic impression of malignant pleural effusion at presentation in sufferers with metastatic non-small-cell lung most cancers. J. Thorac. Oncol. 7, 1485–1489 (2012).
American Thoracic Society. Administration of malignant pleural effusions. Am. J. Respir. Crit. Care Med. 162, 1987–2001 (2000).
Stathopoulos, G. T. & Kalomenidis, I. Malignant pleural effusion: tumor-host interactions unleashed. Am. J. Respir. Crit. Care Med. 186, 487–492 (2012).
Lievense, L. A. et al. Pleural effusion of sufferers with malignant mesothelioma induces macrophage-mediated T cell suppression. J. Thorac. Oncol. 11, 1755–1764 (2016).
Donnenberg, A. D., Luketich, J. D. & Donnenberg, V. S. Secretome of pleural effusions related to non-small cell lung most cancers (NSCLC) and malignant mesothelioma: therapeutic implications. Oncotarget 10, 6456–6465 (2019).
Cornelissen, R. et al. Prolonged tumor management after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant therapy in sufferers with malignant pleural mesothelioma. Am. J. Respir. Crit. Care Med. 193, 1023–1031 (2016).
Murthy, V., Katzman, D. & Sterman, D. H. Intrapleural immunotherapy: an replace on rising therapy methods for pleural malignancy. Clin. Respir. J. 13, 272–279 (2019).
Khanna, S. et al. Malignant mesothelioma effusions are infiltrated by CD3(+) T cells extremely expressing PD-L1 and the PD-L1(+) tumor cells inside these effusions are inclined to ADCC by the anti-PD-L1 antibody avelumab. J. Thorac. Oncol. 11, 1993–2005 (2016).
Tseng, Y. H. et al. PD-L1 expression of tumor cells, macrophages, and immune cells in non-small cell lung most cancers sufferers with malignant pleural effusion. J. Thorac. Oncol. 13, 447–453 (2018).
Ghanim, B. et al. Tumour cell PD-L1 expression is prognostic in sufferers with malignant pleural effusion: the impression of C-reactive protein and immune-checkpoint inhibition. Sci. Rep. 10, 5784 (2020).
Hassan, R. et al. Efficacy and security of avelumab therapy in sufferers with superior unresectable mesothelioma: section 1b outcomes from the JAVELIN Stable Tumor Trial. JAMA Oncol. 5, 351–357 (2019).
Alley, E. W., Katz, S. I., Cengel, Ok. A. & Simone, C. B. II Immunotherapy and radiation remedy for malignant pleural mesothelioma. Transl. Lung Most cancers Res. 6, 212–219 (2017).
Bakker, W., Nijhuis-Heddes, J. M. & van der Velde, E. A. Put up-operative intrapleural BCG in lung most cancers: a 5-year follow-up report. Most cancers Immunol. Immunother. 22, 155–159 (1986).
Yanagawa, H. et al. Intrapleural instillation of interferon gamma in sufferers with malignant pleurisy attributable to lung most cancers. Most cancers Immunol. Immunother. 45, 93–99 (1997).
Sartori, S. et al. Potential randomized trial of intrapleural bleomycin versus interferon alfa-2b by way of ultrasound-guided small-bore chest tube within the palliative therapy of malignant pleural effusions. J. Clin. Oncol. 22, 1228–1233 (2004).
Goey, S. H. et al. Intrapleural administration of interleukin 2 in pleural mesothelioma: a section I–II examine. Br. J. Most cancers 72, 1283–1288 (1995).
Donnenberg, A. D., Luketich, J. D., Dhupar, R. & Donnenberg, V. S. Remedy of malignant pleural effusions: the case for localized immunotherapy. J. Immunother. Most cancers 7, 110 (2019).
Barber, G. N. STING: an infection, irritation and most cancers. Nat. Rev. Immunol. 15, 760–770 (2015).
Woo, S. R. et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41, 830–842 (2014).
Solar, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that prompts the kind I interferon pathway. Science 339, 786–791 (2013).
Deng, L. et al. STING-dependent cytosolic DNA sensing promotes radiation-induced kind I interferon-dependent antitumor. Immun. Immunogenic Tumors Immun. 41, 843–852 (2014).
Baird, J. R. et al. Radiotherapy mixed with novel STING-targeting oligonucleotides ends in regression of established tumors. Most cancers Res. 76, 50–61 (2016).
Shae, D. et al. Endosomolytic polymersomes enhance the exercise of cyclic dinucleotide STING agonists to reinforce most cancers immunotherapy. Nat. Nanotechnol. 14, 269–278 (2019).
Park, C. G. et al. Prolonged launch of perioperative immunotherapy prevents tumor recurrence and eliminates metastases. Sci. Transl. Med. 10, eaar1916 (2018).
Li, L. et al. Hydrolysis of two’3’-cGAMP by ENPP1 and design of nonhydrolyzable analogs. Nat. Chem. Biol. 10, 1043–1048 (2014).
Kato, Ok. et al. Structural insights into cGAMP degradation by Ecto-nucleotide pyrophosphatase phosphodiesterase 1. Nat. Commun. 9, 4424 (2018).
Onyedibe, Ok. I., Wang, M. & Sintim, H. O. ENPP1, an previous enzyme with new features, and small molecule inhibitors-A STING within the story of ENPP1. Molecules 24 (2019).
Belli, S. I., van Driel, I. R. & Goding, J. W. Identification and characterization of a soluble type of the plasma cell membrane glycoprotein PC-1 (5’-nucleotide phosphodiesterase). Eur. J. Biochem. 217, 421–428 (1993).
Fuertes, M. B. et al. Host kind I IFN indicators are required for antitumor CD8+ T cell responses by way of CD8+ dendritic cells. J. Exp. Med. 208, 2005–2016 (2011).
Diamond, M. S. et al. Sort I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208, 1989–2003 (2011).
Gulen, M. F. et al. Signalling power determines proapoptotic features of STING. Nat. Commun. 8, 427 (2017).
Cerboni, S. et al. Intrinsic antiproliferative exercise of the innate sensor STING in T lymphocytes. J. Exp. Med. 214, 1769–1785 (2017).
Chen, J. et al. Sort I IFN protects most cancers cells from CD8+ T cell-mediated cytotoxicity after radiation. J. Clin. Make investments. 129, 4224–4238 (2019).
Broz, M. L. et al. Dissecting the tumor myeloid compartment reveals uncommon activating antigen-presenting cells crucial for T cell immunity. Most cancers Cell 26, 938 (2014).
Laoui, D. et al. The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing results on tumour immunity. Nat. Commun. 7, 13720 (2016).
Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell remedy. Most cancers Cell 31, 711–723 e714 (2017).
Sabatino, M. et al. Era of clinical-grade CD19-specific CAR-modified CD8+ reminiscence stem cells for the therapy of human B-cell malignancies. Blood 128, 519–528 (2016).
Gattinoni, L., Speiser, D. E., Lichterfeld, M. & Bonini, C. T reminiscence stem cells in well being and illness. Nat. Med. 23, 18–27 (2017).
Gattinoni, L. Reminiscence T cells formally be part of the stem cell membership. Immunity 41, 7–9 (2014).
Zhou, T. et al. IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Nature 583, 609–614 (2020).
Scott, A. C. et al. TOX is a crucial regulator of tumour-specific T cell differentiation. Nature 571, 270–274 (2019).
Bosi, A. et al. Pure killer cells from malignant pleural effusion are endowed with a decidual-like proangiogenic polarization. J. Immunol. Res. 2018, 2438598 (2018).
Vacca, P. et al. NK cells from malignant pleural effusions should not anergic however produce cytokines and show robust antitumor exercise on short-term IL-2 activation. Eur. J. Immunol. 43, 550–561 (2013).
Dahan, R. et al. FcgammaRs modulate the anti-tumor exercise of antibodies focusing on the PD-1/PD-L1 axis. Most cancers Cell 28, 285–295 (2015).
Greenwald, R. J., Freeman, G. J. & Sharpe, A. H. The B7 household revisited. Annu Rev. Immunol. 23, 515–548 (2005).
Kinter, A. L. et al. The frequent gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J. Immunol. 181, 6738–6746 (2008).
Bald, T. et al. Immune cell-poor melanomas profit from PD-1 blockade after focused kind I IFN activation. Most cancers Disco. 4, 674–687 (2014).
Dhupar, R. et al. Traits of malignant pleural effusion resident CD8(+) T cells from a heterogeneous assortment of tumors. Int. J. Mol. Sci. 21 (2020).
DeLong, P. et al. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Most cancers Biol. Ther. 4, 342–346 (2005).
Wu, M. F. et al. The M1/M2 spectrum and plasticity of malignant pleural effusion-macrophage in superior lung most cancers. Most cancers Immunol. Immunother. 70, 1435–1450 (2021).
Guo, M. et al. Autologous tumor cell-derived microparticle-based focused chemotherapy in lung most cancers sufferers with malignant pleural effusion. Sci. Transl. Med. 11, eaat5690 (2019).
Li, J., Yang, Y. & Huang, L. Calcium phosphate nanoparticles with an uneven lipid bilayer coating for siRNA supply to the tumor. J. Management. Launch 158, 108–114 (2012).
Liu, Y. et al. An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term management of lung metastases. Nat. Commun. 10, 5108 (2019).
[ad_2]
